Detalhe da pesquisa
1.
Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.
Future Oncol
; 18(19): 2415-2431, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35583358
2.
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 39(1): 81-89, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271807
3.
Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.
Oncol Ther
; 10(2): 411-420, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579821
4.
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Clin Drug Investig
; 42(1): 29-41, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34822128
5.
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 38(10): 1759-1767, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815818
6.
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Curr Med Res Opin
; 37(10): 1779-1788, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34256668